


## PHARMACEUTICAL 2017



## Emmaus Life Sciences Inc. Rank 275 of 292





## PHARMACEUTICAL 2017



## Emmaus Life Sciences Inc. Rank 275 of 292

The relative strengths and weaknesses of Emmaus Life Sciences Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Emmaus Life Sciences Inc. compared to the market average is the variable Research and Development, increasing the Economic Capital Ratio by 84% points. The greatest weakness of Emmaus Life Sciences Inc. is the variable Assets, Current, reducing the Economic Capital Ratio by 268% points.

The company's Economic Capital Ratio, given in the ranking table, is -441%, being 444% points below the market average of 2.9%.

| Input Variable                              | Value in<br>1000 USD |
|---|----------------------|
| Assets, Current                             | 1,210                |
| Cost of Goods Sold                          | 5.5                  |
| Intangible Assets                           | 87                   |
| Liabilities, Current                        | 1,540                |
| Liabilities, Non-Current                    | 36                   |
| Other Assets                                | 14                   |
| Other Compr. Net Income                     | 0                    |
| Other Expenses                              | 1,318                |
| Other Liabilities                           | 0                    |
| Other Net Income                            | -2,087               |
| Other Revenues                              | 0                    |
| Property and Equipment                      | 9.5                  |
| Research and Development                    | 0                    |
| Selling, General and Administrative Expense | 2,530                |

| Output Variable          | Value in<br>1000 USD |
|--------------------------|----------------------|
| Assets                   | 1,320                |
| Liabilities              | 1,577                |
| Expenses                 | 3,854                |
| Revenues                 | 0                    |
| Stockholders Equity      | -256                 |
| Net Income               | -5,941               |
| Comprehensive Net Income | -5,941               |
| Economic Capital Ratio   | -441%                |

